Haran Burri, EHRA 2021: Highlights from EHRA 2021

We caught up with Prof. Haran Burri (Lead Cardiac Physiologist, University of Oxford, Oxford, UK) on his highlights from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What are your highlights from this year’s virtual EHRA 2021 congress? (0.21) Speaker disclosures: Prof. Haran Burri has received institutional fellowship and research support and speaker […]

Artur Fedorowski, EHRA 2021: What’s new in Syncope?

Dr Artur Fedorowski (Associate Professor of Cardiovascular Research, Lund University, Lund, Sweden) gave us an update on what’s new in Syncope, from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: How can we reduce the heterogeneity of syncope diagnosis and management across Europe? (0:21) Could you tell us a little about recent advances […]

Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial

Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]

Haran Burri, EHRA 2021: Biological Pacemakers

Prof. Haran Burri (Lead Cardiac Physiologist, University of Oxford, Oxford, UK) spoke to us on the concept and the current status of biological pacemakers from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: Could you give us a brief overview of the concept of biological pacemakers and the current status of research? (0.21) […]

Cardiovascular Effects of COVID-19 – What Do We Know and Where Should We Go?

Heart International. 2020;14(1):16–9 DOI: https://doi.org/10.17925/HI.2020.14.1.16

The current pandemic of coronavirus disease 2019 (COVID-19) is an unprecedented public health emergency, with worldwide health, social and economic implications. In contrast to other modern epidemics, little prior knowledge of the pathogen existed. Whilst this initially hampered both patient management and the public health response, we have observed a remarkable worldwide attempt to provide […]

A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention

Heart International. 2020;14(2):92-99 DOI: https://doi.org/10.17925/HI.2020.14.2.92

Percutaneous coronary intervention (PCI) has evolved over recent years, with increasingly more complex, high-risk procedures being performed, including in patients with multivessel coronary artery disease with or without left main disease, often complicated by severe left ventricular (LV) dysfunction.1 In addition, decisions about coronary bypass surgery or PCI often focus not only on coronary anatomy, […]

Summary of Practice Considerations for Percutaneous Coronary Intervention of Left Main Bifurcation Disease

Heart International. 2020;14(2):69-72 DOI: https://doi.org/10.17925/HI.2020.14.2.69

Technical approaches to left main (LM) revascularisation by percutaneous techniques continues to be in evolution. This manuscript will attempt to summarise the current best practices for LM percutaneous coronary intervention (PCI). Following a clinical decision for PCI of left main bifurcation (LMB) stenosis, based on angiographic, imaging and functional severity, and supported by current guidelines […]

New Supraventricular Tachycardia Initiative Seeks to Help Patients Find the Best Possible Care and Support

European Journal of Arrhythmia & Electrophysiology. 2021;7(1):Online ahead of journal publication

Supraventricular tachycardia (SVT) is, as its name implies, a tachycardia or elevated heart rate (more than 100 beats per minute) that originates above the ventricles (i.e. in the atria). Or, to use the specific terminology of the European Society of Cardiology (ESC), SVT “literally indicates tachycardia, the mechanism of which involves tissue from the His […]